Characteristics of HIGM3 patients and controls
. | Control group, n = 9 . | Patient 1 . | Patient 2 . |
|---|---|---|---|
| Age, y | 4 (1-10) | 9 | 2 |
| CD3, % | 76.3 (62-81) | 68 | 60 |
| CD4+, % | 67.9 (33-47) | 55 | 24 |
| CD8+, % | 21.6 (20-30) | 13 | 34 |
| Medium, cpm × 10−3* | 0.3 (0.1-0.6) | 0.2 | 0.3 |
| Anti-CD3, cpm × 10−3* | 65 (40-120) | 94 | 39 |
. | Control group, n = 9 . | Patient 1 . | Patient 2 . |
|---|---|---|---|
| Age, y | 4 (1-10) | 9 | 2 |
| CD3, % | 76.3 (62-81) | 68 | 60 |
| CD4+, % | 67.9 (33-47) | 55 | 24 |
| CD8+, % | 21.6 (20-30) | 13 | 34 |
| Medium, cpm × 10−3* | 0.3 (0.1-0.6) | 0.2 | 0.3 |
| Anti-CD3, cpm × 10−3* | 65 (40-120) | 94 | 39 |
Control group values are averages of leukocyte subsets of the age-matched subjects. Ranges for control group values are presented in parentheses.
Lymphocyte proliferation in response to immobilized anti-CD3 or medium alone. T cells from HIGM3 patients and healthy subjects were purified as described in “Patients, materials, and methods” and were cultured for 96 hours in the presence or absence of immobilized anti-CD3 (1 μg/mL). Proliferation was assessed as [3H]-thymidine uptake during the last 16 hours. Results shown are representative of 3 experiments.